BioPharma Resources

Drug Trial Radar · NCT07336472

A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple Myeloma

A Phase I/II, Multicenter, Open-label Study of IBI3003 in Participants With Relapsed or Refractory Multiple Myeloma

Last checked: Nov 19, 2026Latest source record: Sep 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

360

Planned (sponsor's estimate)

Start

Sep 30, 2026

Primary completion

Jun 30, 2027

Study completion Sep 30, 2028

Sponsor

Lead sponsor
Fortvita Biologics (USA)Inc.Industry
Sponsor type
Industry
First posted
Jan 13, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase 1/2 multicenter, open-label, first-in-human study of IBI3003. It includes a phase 1 dose escalation and expansion section to identify maximum tolerated dose(MTD)/recommended Phase 2 Dose(RP2D) of IBI3003, plans to enroll 54\~360 subjects, and a phase 2 stage to explore efficacy, safety and tolerability of IBI3003 at RP2D in multiple myeloma

Conditions

  • Multiple Myeloma

Interventions

  • IBI3003Drug

    Participants will receive IBI3003 treatment until death, disease progression, intolerable toxicity, start of a new anticancer treatment, withdrawal of consent for study participation, or end of the study or for a maximum of 24 months, whichever occurs first.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events (AEs)Time frame: Up to 30 days post last dose
  2. Dose limiting toxicities (DLTs)Time frame: Up to 28 days post first dose
  3. ORRTime frame: up to 24 months
  4. To determine the maximum tolerated dose (MTD) and the recommended Phase 2 Dose (RP2D) of IBI3003Time frame: up to 24 months

Locations

6 sites in 1 country. Site status is shown where the registry gives one.

  • Honor Health

    Scottsdale, Arizona · Active not recruiting

  • City of Hope - Duarte

    Duarte, California · Recruiting

  • City of Hope - Lennar

    Irvine, California · Recruiting

  • Emory

    Atlanta, Georgia · Active not recruiting

  • Memorial Sloan Kettering

    New York, New York · Recruiting

  • MD Anderson

    Houston, Texas · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.